DALI LDL-apheresis: Anticoagulation with r-hirudin in a patient with heparin-induced thrombocytopenia (HIT II)

International Journal of Artificial Organs

Volumn 23, Issue 9, 2000, Pages 637-641

  Thomas, H P ^a   Kassner, U ^a   Schliesser, C ^a   Steinhagen Thiessen, E ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Anticoagulation; DALI; Heparin induced thrombocytopenia; Hirudin; LDL apheresis therapy

Indexed keywords

DIAGNOSIS; LIPOPROTEINS; PATIENT TREATMENT;

ANTI-COAGULATION; BLOOD LEVELS; DIRECT ADSORPTION OF LIPID; FAMILIAL HYPERCHOLESTEROLEMIA; HEPARIN-INDUCED THROMBOCYTOPENIUM; HIRUDIN; LDL-APHERESIS THERAPY; LOW DENSITY LIPOPROTEINS; THROMBOCYTOPENIA; TYPE II;

POLYSACCHARIDES;

ANTICOAGULANT AGENT; ANTITHROMBIN; CITRIC ACID; HEPARIN; LEPIRUDIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT HIRUDIN; THROMBIN;

ADSORPTION; ADULT; ANTICOAGULATION; APHERESIS; ARTICLE; CASE REPORT; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCOAGULABILITY; HYPERLIPOPROTEINEMIA; MALE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033765383     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880002300907     Document Type: Article

References (11)

1. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease
2. DALI-the first whole blood low-density lipoprotein and lipoprotein(a) apheresis system in clinical use: Procedure and clinical results
3. Heparin-induced thrombocytopenia: Pathogenesis, frequency, avoidance and management
4. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis
5. Heparin-induced thrombocytopenia-diagnosis, natural history, and treatment options
6. Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin
7. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet aggregation test and platelet factor 4/heparin enzyme-linked immunosorbent assay
8. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient
9. Quantitative determination of hirudin in blood and body fluids
10. Heparin induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
11. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effect on in vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG